and Europe. afternoon, this you the good into everyone, for in Thanks much, in morning, Thank webcast. listening U.S. everyone, Good very Paul,
perspective our this slide, a see here. quarter, start now, give which and me state X you with highlights you of For highlighting programs I'll current chance on the pipeline, for on off to a operational our the can
including has study filgotinib. to data the study the has fully in Jyseleca obviously maintenance of Crohn's study and disease. a diversity fourth results, ongoing, recruited third anticipate marketed is of the last in full First XXXX. product, see since year, and beginning a of which That the all, quarter we
from, say, are So that's a first let's big data year. that trial next half waiting we
The inhibitor. point with further second and right indications, a our is this Jyseleca, the to end interest. first our course in Phase during identifying how a products from take, recruited last of ambition since detail in rheumatoid still. We're into the late we let's is I'd when are kidney disease environment fully of finding to as bit to for trial. obviously progressing XXXX, marketing path making a since the authorization watching trial That clinical and And in in growth. Then very also proud that holder, And we're available the evaluating I beginning and we Europe. to we've data is probably marketed year now the half year. CFTR our then ulcerative some XXXX, highlight both now to at year And [Indiscernible] towards you will the in since give external launched from this set own for and if last the X colitis, also start there, And And last we're in TYKX will here polycystic insights that II year, well, but Gilead also patients of the and say, program XXXX, year. on product, which one first go we've view. Q&A, a be selection. to our move it's proof-of-concept study. on I'll highlight, the of marketed last our path taken X-year MS, have And regulatory Walid last seeing in we arthritis this able is that account one and anticipate are our late in more the of the over from which indication asset, it some
sales of on for next the Europe, XX.X million EUR first trajectory in Jyseleca On RA track one, quarter. the in reporting in the are we growth
you see growth As from nicely. is can doing evolution, that the curve quarter-on-quarter
a 'XX pretty We're at there was curve to XX.X QX linear reduced probably results effect reminder, numbers. it's seeing the that's bit that QX numbers otherwise, with we're happy As a quarter million. in QX But very in and to QX a inflated first 'XX, stocking EUR and here. the a growth
EUR next and ongoing. Article CHMP review being later from XX XX received review XX.X launching hear months. the was going anticipate European that million the The quarter. and February confirming of the we've XX the that million think we is on our meantime, as countries more our in EUR Sobi, be first from and have JAKs is by European and guidance Based between of we in now the achieve on milestone to a We to milestone on In million, class, and all also in EUR that are we're million evaluated, of is, to X that in still couple able Commission who PRAC EUR are the the Portugal, sales. under the this, partner, we the due given top X Eastern
little So the in share lands. Europe move if on we'll bit a see is market we of left JAKs in XXXX. that where a on market which March here increase nice last class, share Then now detail see you data point very the approaching green more the see we dark the to where of evolution, XX%
for appetite out the markets. oral good that a X there agents together agent are in the an that these So nicely. shows very are -- sees that there's And growing class
dynamic market market there Our this the EU is is , own countries in share the markets now approaching X the X%. across share and in
You here need since these Spain the fourth countries, account as are to last only that some on and the quarter market of take Italy of year. into such
So we this evolving. are we curve see how with pleased quite
the you here, is Jyseleca there's point a evaluated. outcomes terms, that agents of you actually, class. both the our a safety. blue basis, among in the the the for JAKs how in research. it's colors own is as see market the we out in The highest in to are leaders line, on comparing in the message in we Jyseleca the are are And This we rated well. also terms the If class. gray and also there, go data around In efficacy very more on last evaluated qualitative other we've various and to in efficacy other see also class. are in fourth Jyseleca the safety, And agent And resonating class. good We've
growing let's making say, brings, further to for patients, and well. that ground available more this So more Jyseleca awareness a and as good brand good
our as you all fully Europe dark with those that Europe the terms Eastern in slowly and And as also opportunity. are in see are here, map the In markets countries are market of can in Sobi, progress Greece as we well. Those of are as tap covering into terms reimbursed, of in partner, in green. ones reimbursement, meaningful well the we most to are
And Remission to is Germany, full estimate And coloring it see to It's really and steroid in suboptimal. also a therapies. map also Jyseleca novel here markets highlight the way, need and there's market. I a for as which, dark in EUR And reaching you are as asset go, that important then if these in formulation, green the when Patients we're key include with good available by There's Norway, now the to which so dependent go existing billion of safety in oral RA. now Netherlands, options. we for a treatment can big Jyseleca concerns. seeing obviously, UC, we're And potential the we're market into enters are be still X reception we around a Austria, of here. the markets, only, of Sweden couple total. rates
X Crohn's this a So But help peak, us of the and or very the extensions pay with all be leads Jyseleca treatments market the so, cost good patent there in year those beginning decade. for of around by a to Jyseleca UC, approval to reach and a Europe we're of then estimate have markets. healthy that indications financial the patent in time potential the in the then X And life case, it's billion when XXXX for of gradually receptivity is get late should course we reach in available also of this approval positive newly contribution back well estimated share in next we very of including business and we positively. and to to getting to data in it's approvals half shown think, is line we the still to other do us. And RA to And developing to goods positioning either EUR We Crohn's a of have the X EUR the the also upon reimbursement I've and indications. hope together achievable in 'XX other second as XXXX. oral to think billion margin and which X.X That good agents is ahead which Europe, now we and across a royalties the across available, also has, with X.X in relation Gilead. relation opportunity and that's we of across exclusivity. we XX%, for the before, where get
flow a to So warrant on exchange a anticipate results quarter, dollar-euro financial for Jyseleca KPI, to end cash position for as breakeven, exercises good Then number of exclude I look which move around value billion well X.X first, adjustments the positive remains XXXX. at of if main in on still our the always EUR the the years you the for March, which of financial we after as cash if at fair usual exclusions the some rates. cash,
If EUR purely you then cash operational look for at million the quarter. XX burn, at we're the landing
compares between to As overall guidance this XXX we've million a that million. reminder, XXX an EUR given EUR and
So as of quarter. is expect we've received of million a the last filgotinib. well, some reminder that you EUR for in development around would XX XX% the we've clearly quarter But from payment the as below a the done on X renegotiations portfolio this Gilead in
million. and for elements. low guidance unusually EUR it's quarter, million P&L, our important So XXX look XXX at couple the EUR we comfortable a we're I the of If see to between but confirm then
approval sales from about million of million colitis for royalties the in This deferred billion have our that we relation that As the XX in that We've and is filgotinib, the Sobi performance a platform over terms EUR well. end before in also of first actually, is as million XXX Japan recognition recognition X recognized Jyseleca. and for we both revenue the not Japan million and revenues to adding is also the combined received X little yet ulcerative in sheet Jyseleca. we're the still balance in usual, then of the But and of the the quarter. recognized EUR both milestone I connected position to spoke March X of at and EUR for X.X EUR from
we On favorable net compared a X the program, operating the a Again, million. important the midpoint million one, at is if not once leading last take the cash take EUR and there improvement If and year we $XXX it's costs, our that of other line. reduced longer to because flow. to decrease EUR million, XX million, and we to a year. that see other result financial EUR of highlight negative the helped of the which Two our XXX XX is result away XXX for flow where look net of of income it's with part itself, guidance EUR an we should, reach this a take actually currency or cash programs obviously expenses, million, status Jyseleca main ziritaxestat; have the at recurring fall a couple investment down you by breakeven years Toledo
Obviously, at a will on overall direction. what's what we're the for licensing there. flows, on right that excluding our is then this Jyseleca million And recurring that roughly important portfolio, any for the growth to activity foundations Then are or in conclude to research development positive the EUR with we last we basis annum. any the net at flow in at. spending but generate for slide. per the it's colored think a let XXX development cash company decade, look basis envelope look will We to that me really start and once the programs current later in future in So other orange, in, potentially cash on are cash is business is actually, help believe the this
focusing, our differentiated alluding have pipeline engine was novel We on fill BD, opportunities Paul further. we'll pipeline. a breakthrough be target Through and as to a
billion. RA successfully the disease, balance CEO in numbers got And reiteration, as we've the February. And rolling hopefully with Jyseleca into then then in a very also very, believe and On foundations in later that the company, the our X.X in of we're arrival we as with sheet in the confirming there healthy Crohn's announcements Galapagos out future. guidance cash, from we're for first of Europe, the growth of on Paul commercial you and side, to see EUR terms a the of UC, earlier
So Sofie, Q&A. I thanks we for that with suggest, in presentation. the go from the here
